SCHEMBL5871929

SCHEMBL5871929

CCCOC(=O)C(=Cc1cc[c]cc1)C(=O)OCCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.54
MEN1 O00255 6/20 0.54
MAPT P10636 7/20 0.50
LMNA P02545 5/20 0.50
NPSR1 Q6W5P4 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
S1PR4 O95977 1/20 0.50
S1PR1 P21453 1/20 0.50
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 3/20 0.43
MITF O75030 1/20 0.43
NR1H4 Q96RI1 1/20 0.42
HSP90AA1 P07900 2/20 0.40
HTT P42858 1/20 0.40
POLB P06746 2/20 0.39
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871410 0.91 MEN1 (0.51) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL5871779 0.89 MEN1 (0.50) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL5872051 0.88 MEN1 (0.49) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL5872078 0.87 MEN1 (0.72) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL15673470 0.85 KMT2A (0.74) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL12869950 0.82 MEN1 (0.56) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL8472995 0.81 KMT2A (0.54) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL28213002 0.81 MEN1 (0.84) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL31483425 0.79 NR1H4 (0.57) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL28126890 0.79 KMT2A (0.53) KMT2AMEN1MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 KMT2A 4290/4885MEN1 3746/4885MAPT 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.